Inhibitex Veronate update
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Panel of experts will review the firm's Veronate polyclonal immune globulin development program in May, with an assessment due "near the end of June," the firm says. However, "regardless of what we ultimately determine was the cause" of earlier disappointing Phase III results, the firm does not foresee conducting additional clinical trials in very low birth weight infants "with our current donor-selected immune globulin form" of the biologic, Inhibitex states April 28. Earlier in April, Inhibitex reported that Veronate missed all endpoints in a Phase III trial for prevention of hospital-associated infections in premature, very low birth weight infants. Inhibitex "will halt the manufacture of the clinical trial material it has used in the clinical development of Veronate to-date"...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 9 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.